Brentuximab vedotin: A nursing perspective on best practices and management of associated adverse events Journal Article


Authors: Clifford, K.; Copeland, A.; Knutzen, G.; Samuelson, E.; Grove, L.; Schiavo, K.
Article Title: Brentuximab vedotin: A nursing perspective on best practices and management of associated adverse events
Abstract: BACKGROUND: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30-expressing cells. OBJECTIVES: This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell lymphoma trials, and shares practical tips that may help decrease occurrence and severity. METHODS: Peer-reviewed literature was surveyed to collect safety data from sponsored clinical trials of BV and to compile associated management guidelines. FINDINGS: Peripheral neuropathy was the most common BV-associated AE across clinical trials. Other clinically relevant AEs included neutropenia, infection, and infusion-related reactions. Awareness of and preparedness for these common BV-associated AEs and other less common but significant AEs will help nurse clinicians and patients maximize the clinical benefit for patients receiving BV. © 2018, Oncology Nursing Society. All rights reserved.
Keywords: peripheral neuropathy; management; adverse events; brentuximab vedotin
Journal Title: Clinical Journal of Oncology Nursing
Volume: 22
Issue: 4
ISSN: 1092-1095
Publisher: Oncology Nursing Society (ONS)  
Date Published: 2018-08-01
Start Page: e103
End Page: e114
Language: English
DOI: 10.1188/18.cjon.e103-e114
PROVIDER: scopus
PUBMED: 30035778
DOI/URL:
Notes: Article -- Export Date: 1 November 2018 -- Source: Scopus
Altmetric Score
MSK Authors